Fig. 1
From: MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer
MUC16 and Siglec-9 were associated with inflammation and neutrophil infiltration in ovarian cancer. (A) The correlation between the proportion and count of peripheral blood cells, serum inflammatory-related factors and serum MUC16 (CA125) level in ovarian cancer patients (n = 99). (N: count of peripheral blood neutrophil; N%: proportion of peripheral blood neutrophil; L: count of peripheral blood lymphocytes; L%: proportion of peripheral blood lymphocytes; M: count of peripheral blood monocytes; M%: proportion of peripheral blood monocytes) (B) The correlation among MUC16, inflammation pathways, neutrophils, and macrophages in ovarian cancer according to TCGA Ovarian Cancer (TCGA-OV) dataset with GSVA. (C) The correlation between MUC16 and the inflammatory factors IL-6 and IL-1B expression according to TCGA-OV. (D-E) The correlation between Siglec-9 and the markers of neutrophils (D) and neutrophil infiltration (E) based on TCGA-OV database and ovarian cancer tissue RNA sequencing data. (F) Immunohistochemical staining on serial sections of ovarian cancer tissue with CD11b and Siglec-9 in two different patients (Case 1 and Case 2). (G) Detection of the expression of Siglec-9 of neutrophils from peripheral blood of ovarian cancer patients and umbilical cord blood by flow cytometry. (A-C: R = Pearson’s correlation; D-E: rho = Spearman correlation; NLR: neutrophil-to-lymphocyte ratio. PBN: peripheral blood neutrophils; UCBN: umbilical cord blood-derived neutrophils; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.)